Mesenchymal stem and non-stem cell surgery, rescue, and regeneration in glaucomatous optic neuropathy

Stem Cell Research & Therapy

Enzo Maria Vingolo¹  Federica Franzone¹  Marcella Nebbioso²  Paolo Giuseppe Limoli³  Celeste Limoli³ 

[1] Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy;Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy;Department of Sense Organs, Ocular Electrophysiology Centre, Umberto I Policlinic, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy;Low Vision Research Centre of Milan, Piazza Sempione 3, 20145, Milan, Italy;

关键词: Adipose-derived stem cell;    Autograft;    Cell surgery;    Glaucoma;    Glaucomatous optic neuropathy;    Growth factor (GF);    Limoli retinal restoration technique (LRRT);    Mesenchymal stem cell (MSC);    Platelet-rich plasma;    Stem cells;   

DOI  :  10.1186/s13287-021-02351-4

来源: Springer

【 摘 要 】

BackgroundGlaucomatous optic neuropathy (GON) is an anatomofunctional impairment of the optic nerve triggered by glaucoma. Recently, growth factors (GFs) have been shown to produce retinal neuroenhancement. The suprachoroidal autograft of mesenchymal stem cells (MSCs) by the Limoli retinal restoration technique (LRRT) has proven to achieve retinal neuroenhancement by producing GF directly into the choroidal space. This retrospectively registered clinical study investigated the visual function changes in patients with GON treated with LRRT.MethodsTwenty-five patients (35 eyes) with GON in progressive disease conditions were included in the study. Each patient underwent a comprehensive ocular examination, including the analysis of best corrected visual acuity (BCVA) for far and near visus, sensitivity by Maia microperimetry, and the study of the spectral domain-optical coherence tomography (SD-OCT). The patients were divided into two groups: a control group, consisting of 21 eyes (average age 72.2 years, range 50–83), and an LRRT group, consisting of 14 eyes (average age 67.4, range 50–84).ResultsAfter 6 months, the BCVA, close-up visus, and microperimetric sensitivity significantly improved in the LRRT-treated group (p<0.05), whereas the mean increases were not statistically significant in controls (p>0.5).ConclusionsPatients with GON treated with LRRT showed a significant increase in visual performance (VP) both in BCVA and sensitivity and an improvement of residual close-up visus, in the comparison between the LRRT results and the control group. Further studies will be needed to establish the actual significance of the reported findings.

【 授权许可】

CC BY